UnknownNot Applicable

LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT

Denmark130 participantsStarted 2020-09-29

Plain-language summary

Older patients with non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT) often die from other causes than lung cancer due to age-related comorbidities. This national randomized study will include 130 patients throughout 5 Danish cancer centres and investigate if a comprehensive geriatric intervention (CGA) when added upfront to SBRT for patients with localized NSCLC will have an impact on quality of life (QoL), overall survival, physical functionality and unplanned hospital admissions. If an upfront CGA improves patients' general health status, this study could lead to implementation of a CGA in standard clinical practice as well as further research on older patients receiving radiotherapy.

Who can participate

Age range70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with cytologically or histologically proven non-small cell lung cancer * Stage T1-3N0M0 * ≥ 70 years old * In a multidisciplinary setting the patient is considered medically inoperable, too frail for operation due to age and/or comorbidity or that the patient refuse surgery and therefore candidate for SBRT. Exclusion Criteria: * Missing histology/cytology * Another current malignancy * Higher staging at treatment planning * Not able to provide informed consent * Do not speak or understand Danish

What they're measuring

Quality of Life (EQ-5D)

Timeframe: 12 months

Trial details

NCT IDNCT05919641

SponsorOdense University Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-04-01

Contact for this trial

Kristian K Bentsen, Dr.med.

004528735210 kristian.kirkelund.bentsen3@rsyd.dk

View on ClinicalTrials.gov More Non-small Cell Lung Cancer trials